Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-012-0 | CAS number: 1072-63-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
1-vinylimidazole was not a skin sensitiser in a local lymph node assay in the mouse.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK, Manston Road, Margate, Kent CT9 4LT, United Kingdom
- Age at study initiation: pre-test 1 and 3: 9-10 weeks, pre-test 2 and main study: 8-9 weeks
- Weight at study initiation: 17.1-20.3 g
- Housing: Animals were group housed in Makrolon Type III cages, with wire mesh top (EHRET GmbH, 79302 Emmendingen, Germany) and granulated soft wood bedding (Rettenmaier & Söhne GmbH + Co. KG, 73494 Rosenberg, Germany).
- Diet: Pelleted standard diet, ad libitum (Harlan Laboratories B.V., 5960 AD Horst, Netherlands)
- Water: Tap water, ad libitum (Gemeindewerke, 64380 Rossdorf, Germany)
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 44 - 109
- Photoperiod (hrs dark / hrs light): 12 / 12 - Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 1, 2.5, and 5 % (w/w)
- No. of animals per dose:
- 5
- Details on study design:
- Three groups each of five female mice were treated with different concentrations of the test item by topical application at the dorsum of each ear once daily each on three consecutive days. A control group of five mice was treated with the vehicle only. Five days after the first topical application, the mice were intravenously injected into a tail vein with radio-labelled thymidine (3H-methyl thymidine; 3HTdR). Approximately five hours after intravenous injection, the mice were sacrificed and the draining auricular lymph nodes excised, pooled per animal and immediately weighed using an analytical balance. Both ears were punched at the apical area and the punches were immediately weighed pooled per animal. Afterwards, single cell suspensions of lymph node cells were prepared from lymph nodes pooled per animal. An aliquot of each cell suspension was used for determination of lymph node cell count. The suspensions were washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3H-methyl thymidine measured in a β-scintillation counter.
- Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- The mean values and standard deviations were calculated in the body weight tables and for the DPM values (group mean DPM ± standard deviation) as well as for the ear weights, lymph node weights and lymph node cell counts.
A statistical analysis was conducted on the DPM values, the ear weights, the lymph node weights and the lymph node cell count to assess whether the difference was statistically significant between test item groups and negative control group.
For all statistical calculations SigmaStat for Windows (Version 2.0) was used. A One-Way-Analysis-of-Variance was used as statistical method. In case of significant results of the One-Way-ANOVA, multiple comparisons were performed with the Dunnett test. Statistical significance was set at the five per cent level (p < 0.05).
However, both biological and statistical significance were considered together. - Positive control results:
- Mean DPM per animal and S.I. (a-hexyl cinnamalderhyde in AOO)
0 % (w/v): DPM = 460, S.I. = 1.00
5 % (w/v): DPM = 621.1, S.I. = 1.35
10 % (w/v): DPM = 1004.3, S.I. = 2.18
25 % (w/v): DPM = 3720.5. S.I. = 8.08 - Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- vehicle (AOO 4+1 v/v)
- Parameter:
- SI
- Value:
- 1.02
- Test group / Remarks:
- 1% test substance
- Parameter:
- SI
- Value:
- 0.81
- Test group / Remarks:
- 2.5% test substance
- Parameter:
- SI
- Value:
- 1.11
- Test group / Remarks:
- 5% test substance
- Cellular proliferation data / Observations:
- - Viability / Mortality: No deaths occurred during the study period.
- Clinical Signs: No systemic findings were observed during the study period. On day 3 only, a slight erythema of the ear skin was observed in the high dose group. In the other groups, no signs of local skin irritation were observed.
- Body Weights: The body weight of the animals, recorded prior to the first application and prior to treatment with 3HTdR, was within the range commonly recorded for animals of this strain and age.
- Lymph Node Weights and Cell Counts: The measured lymph node weights and –cell counts of all animals treated were recorded after sacrifice. No statistically significant or biologically relevant increase in lymph node weights or lymph node cell count was not observed in any of the test item treated groups in comparison to the vehicle control group.
- Ear Weights: The measured ear weights of all animals treated were recorded after sacrifice. A statistically significant or biologically relevant increase in ear weights was not observed in any treated group in comparison to the vehicle control group. - Interpretation of results:
- GHS criteria not met
Reference
DPM per group [mean +/- SD]:
- vehicle (AOO 4 +1 v/v): 866.4 +/- 242.4
- 1% test substance: 881.0 +/- 252.8
- 2.5% test substance: 704.0 +/- 338.3
- 5% test substance: 959.6 +/- 187.8
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The skin sensitising properties of 1-vinylimidazole were determined in a GLP study according to OECD429 (Local Lymph Node Assay (LLNA)) and EU method B.42 (2011; RL1). For this purpose, three groups of 5 female mice each were treated with increasing concentrations of 1-vinylimidazole (1%, 2.5% and 5% in vehicle, respectively) applied on the dorsum of both ears (25 µL per ear) for three consecutive days. Three days after the last treatment, all animals received an intravenous injection of3H-methyl Thymidine (3HTdR). Five hours later, the3HTdR incorporation in the draining auricular lymph nodes was determined. The results were compared with those of a control group which was treated with the vehicle (acetone:olive oil, 4:1 v/v). A positive control group treated with α-hexyl cinnamaldehyde (up to 25% HCA solution in acetone:olive oil, 4:1 v/v) was included in the report as a reliability check. A slight erythema of the ear skin was observed in the high dose group. In the other groups, no signs of local skin irritation were observed. Stimulation indices (SIs) of 1.02, 0.81 and 1.11 were calculated in response to a 1%, 2.5% and 5% 1-vinylimidazole concentration, respectively. Since the SIs were lower than 3 at all concentrations the results indicted that 1-vinylimidazole should not be considered a skin sensitiser (a SI of 3 is the limiting value required for classification as a skin sensitiser).
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the results of the skin sensitisation study, 1-vinylimidazole does not need to be classified according to the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
